Leerink Partners analyst, Danielle Antalffy, cut her PT on Medtronic (NYSE: MDT) as sales growth was offset by weaker margins ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE